undamentalytics Newsletter
Sign in

Vistagen Therapeutics, Inc. key statistics and ratios

In fiscal 2026, Vistagen Therapeutics, Inc. had return on equity of -131.6% and a net margin of -5491.3%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Mar 20112012Mar 20122013Mar 20132016Mar 20162017Mar 20172018Mar 20182020Mar 20202021Mar 20212022Mar 20222023Mar 20232024Mar 20242025Mar 20252026Mar 2026LTMJun 2026
Net margin−457.9%−909.7%<−999%—−820.4%——<−999%<−999%—<−999%<−999%<−999%<−999%
Return on equity———————−41.6%−61.0%−154.3%−46.5%−55.7%−131.6%—
Return on assets<−999%<−999%<−999%<−999%−436.2%−191.4%−243.7%−31.4%−52.2%−123.8%−40.6%−49.4%−104.9%−160.4%
R&D as % of revenue177.6%401.5%>999%—416.3%——>999%>999%—>999%>999%>999%>999%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $36m
Short-term assets $34mLonger-term assets $1m
What it owes, and who funded it · $36m
Short-term liabilities $11mLonger-term liabilities $0mShareholders' equity $24m
  • Short-term assets cover short-term liabilities $34m of assets due within a year against $11m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $34m short-term assets against $63,000 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Vistagen Therapeutics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

10 /100

Weak moat

How hard Vistagen Therapeutics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -193.3% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -1562.3%; its worst year was -9233.1%.

  • Cash conversion 2 / 20

    Free cash flow was positive in 1 of 5 years, at a median -2968.1% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 2560.4% over five years; stock-based pay has been a median 153.9% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (15 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: KRRO vs VTGNCLGN vs VTGNUPB vs VTGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Vistagen Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Vistagen Therapeutics, Inc.